The Impact of Glycated Hemoglobin (HbA1c) on Cardiovascular Disease Risk: A Mendelian Randomization Study Using UK Biobank
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glycated hemoglobin (HbA1c) is positively associated with cardiovascular disease (CVD), although evidence is primarily observational. Mendelian randomization studies have only examined its relation with subtypes of CVD. We examined the relation of HbA1c with CVD and its subtypes in the UK Biobank using Mendelian randomization. RESEARCH DESIGN AND METHODS: We used 38 genetic variants strongly and independently related to HbA1c (n = 123,665) applied to the UK Biobank (n = 392,038). We used inverse variance weighting (IVW) to obtain the associations of HbA1c with CVD, coronary artery disease (CAD), and stroke (overall and stroke subtypes). Sensitivity analyses included Mendelian randomization (MR)-Egger, a weighted median, and exclusion of potentially invalid single nucleotide polymorphisms (SNPs). We also applied the same genetic instruments to CARDIoGRAMplusC4D (Coronary ARtery DIsease Genome wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics) 1000 Genomes–based genome-wide association study (n = 184,305) as a validation for CAD. RESULTS: In the UK Biobank, HbA1c was not associated with CVD using IVW (odds ratio [OR] 1.11 per %, 95% CI 0.83–1.48). However, HbA1c was associated with increased CAD risk (OR 1.50 per %, 95% CI 1.08–2.11) with directionally consistent results from MR-Egger and weighted median. The positive association with CAD was more pronounced when we excluded potentially invalid SNPs (OR 2.24 per %, 95% CI 1.55–3.25). The positive association was replicated in CARDIoGRAM (OR 1.52 per %, 95% CI 1.03–2.26). The association of HbA1c with stroke and its subtypes was less clear given the low number of cases. CONCLUSIONS: HbA1c likely causes CAD. The underlying mechanisms remain to be elucidated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 1×
“To address these research gaps, we implemented a two-sample Mendelian randomization study to assess the relation of HbA1c with CVD and its subtypes by using genetic predictors of HbA1c from the most up-to-date genome-wide association study (GWAS) of HbA1c in MAGIC (Meta-Analyses of Glucose and InsulinRelated Traits Co…”
MethodEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 1×
“We conducted MR-Egger regression, which produces valid estimates even if all the genetic instruments are invalid, as long as the InSIDE (Instrument Strength Independent of Direct Effect) assumption holds (29).”
MethodBowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922 · cited 1×
“We also used a weighted median, which produces valid estimates as long as more than 50% of the information is derived from valid SNPs (30).”
MethodEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707 · cited 3×
“†Set 2: SNP excluded if classified as erythrocytic based on the HbA1c GWAS or associated with potential causes of CAD or confounders based on public data sources (GWAS Catalog and PhenoScanner) and UK Biobank. care.diabetesjournals.org Au Yeung, Luo, and Schooling 1995 consistent results for HbA1c on CAD for these dif…”
MethodInfluentialExternal validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544 · cited 1×
“observational studies, whether results from these trials, which are primarily in people with diabetes, generalize to the general population is uncertain (12).”
ResultA comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization
Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N., & Thompson, J. (2017) · Statistics in Medicine · doi:10.1002/sim.7221 · Cited by 1,887 · cited 1×
“yses excluding potentially pleiotropic SNPs, which may violate the exclusionrestriction assumption (38).”
BackgroundWing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Lindström, J., Ilanne-Parikka, P., Peltonen, M., Aunola, S., Eriksson, J. G., Hemiö, K., Hämäläinen, H., Härkönen, P., Keinänen-Kiukaanniemi, S., Laakso, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69701-8 · Cited by 1,799
Feigin, V. L., Roth, G. A., Naghavi, M., Parmar, P., Krishnamurthi, R., Chugh, S., Mensah, G. A., Norrving, B., Shiue, I., Ng, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30073-4 · Cited by 1,691
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
PhenoScanner: a database of human genotype-phenotype associations.
Staley, J. R., Blackshaw, J., Kamat, M. A., Ellis, S., Surendran, P., Sun, B. B., Paul, D. S., Freitag, D., Burgess, S., Danesh, J., et al. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw373 · Cited by 1,479 · cited 1×
“First, we excluded SNPs related to potential causes of CAD based on the GWAS Catalog (31)/PhenoScanner (32) and SNPs associated with potential confounders in the UK Biobank (set 1).”
MethodTriangulation in aetiological epidemiology
Lawlor, D. A., Tilling, K., & Davey Smith, G. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyw314 · Cited by 1,129 · cited 2×
“Considering triangulation of the evidence from different designs with different underlying assumptions, HbA1c may be causal in the development of CAD in the general population (28).”
BackgroundWhat makes UK Biobank special?
Collins, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60404-8 · Cited by 1,128
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035 · cited 1×
“intensive glycemic control did not substantially reduce the risk of cardiovascular disease (CVD) events and may even have increased overall mortality (5), which remained evident after prolonged follow-up (6,7).”
BackgroundChen, Z., Chen, J., Collins, R., Guo, Y., Peto, R., Wu, F., Li, L., & on behalf of the China Kadoorie Biobank (CKB) collaborative group (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr120 · Cited by 1,034
Huang, Y., Cai, X., Mai, W., Li, M., & Hu, Y. (2016) · BMJ · doi:10.1136/bmj.i5953 · Cited by 1,012
Why Representativeness Should Be Avoided
Rothman, K. J., Gallacher, J. E., & Hatch, E. E. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys223 · Cited by 861
Wheeler, E., Leong, A., Liu, C.-T., Hivert, M.-F., Strawbridge, R. J., Podmore, C., Li, M., Yao, J., Sim, X., Hong, J., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002383 · Cited by 408 · cited 3×
“, invalid) (21), leaving 14 SNPs (set 2).”
MethodHeight, body mass index, and socioeconomic status: mendelian randomisation study in UK Biobank
Tyrrell, J., Jones, S. E., Beaumont, R., Astley, C. M., Lovell, R., Yaghootkar, H., Tuke, M., Ruth, K. S., Freathy, R. M., Hirschhorn, J. N., et al. (2016) · BMJ · doi:10.1136/bmj.i582 · Cited by 372
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195 · cited 1×
“Notably, some of the agents used to achieve glycemic control, such as sulphonylureas, have been implicated in CVD (13).”
BackgroundNine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes
The ACCORD Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2283 · Cited by 193 · cited 1×
“intensive glycemic control did not substantially reduce the risk of cardiovascular disease (CVD) events and may even have increased overall mortality (5), which remained evident after prolonged follow-up (6,7).”
BackgroundSarwar, N., Aspelund, T., Eiriksdottir, G., Gobin, R., Seshasai, S. R. K., Forouhi, N. G., Sigurdsson, G., Danesh, J., & Gudnason, V. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000278 · Cited by 175
Woodfield, R., Grant, I., UK Biobank Stroke Outcomes Group, UK Biobank Follow-Up and Outcomes Working Group, & Sudlow, C. L. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140533 · Cited by 145
Cited by
Personalized Medicine and the Power of Electronic Health Records
Abul-Husn, N. S., & Kenny, E. E. (2019) · Cell · doi:10.1016/j.cell.2019.02.039 · Cited by 355
Brower, M. A., Hai, Y., Jones, M. R., Guo, X., Chen, Y. D. I., Rotter, J. I., Krauss, R. M., Legro, R. S., Azziz, R., & Goodarzi, M. O. (2019) · Human Reproduction · doi:10.1093/humrep/dey343 · Cited by 115
Benn, M., Emanuelsson, F., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2021) · Diabetologia · doi:10.1007/s00125-021-05436-0 · Cited by 41
Metadata
- Authors
- Au Yeung, S. L., Luo, S., & Schooling, C. M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-06-27
- Volume
- 41
- Issue
- 9
- Pages
- 1991-1997
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2809991789
- Cited by
- 92
- References
- 29
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.